Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

Moritz Fürstenau; Georg Hopfinger; Sandra Robrecht; Anna-Maria Fink; Othman Al-Sawaf; Petra Langerbeins; Paula Cramer; Julia Von Tresckow; Christian Maurer; Nadine Kutsch; Manuela Hoechstetter; Martin Dreyling; Elisabeth Lange; Michael Kneba; Stephan Stilgenbauer; Hartmut Döhner; Manfred Hensel; Michael G Kiehl; Ulrich Jaeger; Clemens-Martin Wendtner; Valentin Goede; Kirsten Fischer; Michael von Bergwelt-Baildon; Barbara Eichhorst; Michael Hallek; Sebastian Theurich

doi:10.1038/s41375-019-0630-6

Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

Leukemia. 2020 Apr;34(4):1177-1181. doi: 10.1038/s41375-019-0630-6. Epub 2019 Nov 14.

Authors

Moritz Fürstenau¹, Georg Hopfinger², Sandra Robrecht³, Anna-Maria Fink³, Othman Al-Sawaf³, Petra Langerbeins³, Paula Cramer³, Julia Von Tresckow³, Christian Maurer³, Nadine Kutsch³, Manuela Hoechstetter⁴, Martin Dreyling⁵, Elisabeth Lange⁶, Michael Kneba⁷, Stephan Stilgenbauer^{8

9}, Hartmut Döhner⁸, Manfred Hensel¹⁰, Michael G Kiehl¹¹, Ulrich Jaeger¹², Clemens-Martin Wendtner⁴, Valentin Goede¹³, Kirsten Fischer³, Michael von Bergwelt-Baildon⁵, Barbara Eichhorst³, Michael Hallek³, Sebastian Theurich^{14

15

16}

Affiliations

¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. [email protected].
² Department of Internal Medicine I, Bone Marrow Transplantation, Medical University of Vienna, Vienna, Austria.
³ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
⁴ Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
⁵ Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
⁶ Evangelisches Krankenhaus Hamm, Hamm, Germany.
⁷ Department II of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
⁸ Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
⁹ Department of Hematology, Oncology and Rheumatology and José Carreras Center for Immuno and Gene Therapy, Saarland University Medical School, Homburg/Saar, Germany.
¹⁰ Mannheim Oncology Practice, Mannheim, Germany.
¹¹ Department of Internal Medicine, Frankfurt (Oder) General Hospital, Frankfurt/Oder, Germany.
¹² Department of Medicine I, Clinical Division of Hematology and Hemostaseology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
¹³ Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
¹⁴ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. [email protected].
¹⁵ Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. [email protected].
¹⁶ Gene Center, Cancer- and Immunometabolism Research Group, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. [email protected].

PMID: 31728057
DOI: 10.1038/s41375-019-0630-6

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
Clinical Trials, Phase III as Topic
Female
Follow-Up Studies
Humans
Immunotherapy / mortality*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Male
Middle Aged
Obesity / physiopathology*
Prognosis
Prospective Studies
Rituximab / administration & dosage
Sex Factors
Survival Rate
Vidarabine / administration & dosage

Substances

Rituximab
Bendamustine Hydrochloride
Vidarabine